Exicure Taps Timothy Walbert as Chairman
7:19AM ET 4/07/2020 MT NewswiresExicure (XCUR) said pre-market Tuesday that Timothy Walbert has been appointed as chairman, succeeding Chad Mirkin, who is stepping down due to his...
Quotes Snapshot > XCUR
Exicure Inc XCUR:NASDAQ
Last Price$1.61NASDAQ Closing Price as of 3:59PM ET 4/07/20
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.20(14.18%)
Bid (Size)$1.11 (1)
Ask (Size)$1.71 (1)
Day Low / High$1.42 - 1.66
Volume202.4 K
Read more news Recent News
Exicure Maintaining R&D Operations Amid COVID-19 Pandemic
7:23AM ET 3/31/2020 MT NewswiresExicure (XCUR), a clinical-stage biotechnology company, said Monday it continues to conduct research and development activities despite the ongoing...
Insider Trends: 90-Day Buying Trend Extended with Insider Purchase of Exicure Stock
8:49AM ET 3/16/2020 MT NewswiresDr David R Walt, Director, purchased 291,066 shares of Exicure (XCUR) on Mar 13, 2020, for $352,859. Dr Walt, after the transactions described in the SEC...
Insider Makes Significant Stock buy in Exicure (XCUR) Shares Breaks neutral Trend of Last 90 Days
10:19PM ET 12/24/2019 MT NewswiresSubstantial insider buying activity was disclosed in Exicure shares in a form 4 document filed with the SEC today, showing -- Bali Muralidhar, Director --...
View all Commentary and Analysis
Exicure (XCUR) Presents At Cowen Health Care Conference - Slideshow
7:24AM ET 3/05/2020 Seeking AlphaExicure: Evaluating A $2 Biotech Stock
6:43PM ET 2/26/2020 Seeking AlphaDaily Insider Ratings Round Up 12/23/19
4:20PM ET 12/26/2019 Seeking Alpha2020 Outlook For Medical Stocks: Greater Selectivity But Continued Consolidation And Favorable Developments
1:21PM ET 12/16/2019 Seeking AlphaCompany Profile
Business DescriptionExicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. View company web site for more details
| Address | 8045 Lamon Avenue Skokie, Illinois 60077 |
| Phone | +1.847.673.1700 |
| Number of Employees | N/A |
| Recent SEC Filing | 03/30/2020 8-K |
| Chief Executive Officer & Director | David A. Giljohann |
| Chief Operating Officer | Matthias Schroff |
| Chief Financial Officer | David S. Snyder |
| Vice President & Head-Business Development | Jocelyn Trokenheim |
Company Highlights
| Price Open | $1.50 |
| Previous Close | $1.41 |
| 52 Week Range | $0.96 - 3.84 |
| Market Capitalization | $140.3 M |
| Shares Outstanding | 87.2 M |
| Sector | Commercial Services |
| Industry | Miscellaneous Commercial Services | Next Earnings Announcement | N/A |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.45 |
| Beta vs. S&P 500 | N/A |
| Revenue | $118.0 K |
| Net Profit Margin | -2,029.55% |
| Return on Equity | -60.73% |
Analyst Ratings as of 11/19/2019
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |